Aging-US is dedicated to advancing our understanding of the biological mechanisms that drive aging and the development of age-related diseases. Our mission is to serve as a platform for high-quality ...

Palvella Therapeutics completed a Phase 3 trial for QTORIN™ rapamycin, targeting a rare genetic disease, with results expected in 2026. Top-line results from the SELVA trial are expected in the first ...

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common ...

WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...

Palvella remains on track to submit an NDA in the second half of 2026. Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause per ...

For centuries, humans have searched for ways to extend life. Alchemists never found the philosopher's stone, but scientists have consistently shown that a longer life can be attained by eating less—at ...

Add Yahoo as a preferred source to see more of our stories on Google. Rapamycin has been hyped as a longevity breakthrough and even the fountain of youth, but new research says the excitement is ...

The longevity and bio-hacking sector of medicine is known to be highly experimental, with a lot being pushed by fitness and health influencers that still requires significant testing. Also Read | ...

The anti-aging drug Rapamycin has the same life-extending effect as eating less, according to new research from the University of East Anglia and University of Glasgow. Dietary restriction has long ...

For centuries, humans have searched for ways to extend life. Alchemists never found the philosopher’s stone, but scientists have consistently shown that a longer life can be attained by eating less – ...